Optimized binuclease fusions and methods
US12077790B2 · kind B2 · utility
0Cited by
130References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 23, 2021 |
| Grant date | Sep 3, 2024 |
| Priority date | — |
| Expiry date | May 12, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides for optimized binuclease fusion proteins with increased pharmacokinetic properties. The optimized binuclease fusion proteins of the invention two or more nuclease domains (e.g., RNase and DNase domain) operably coupled to an Fc domain. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.